Document is current
Any future updates will be listed below
-
Authors
Iyengar, Meera
Jain, Animesh
Herfarth, Hans H.
Long, Millie D.
Barnes, Edward L.
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (K23DK127157)
- License Information
-
More Information
Article History
Received: 21 January 2025
Accepted: 30 May 2025
First Online: 26 June 2025
Declarations
:
: Millie D. Long has served as a consultant for AbbVie, Pfizer, Takeda, Eli Lilly, Bristol-Meyers Squibb, Target RWE, and Prometheus and has received research support from Pfizer, Takeda, and Janssen. Hans H. Herfarth has served as a consultant for Alivio, AMAG, BMS, Boehringer, ExeGi Pharma, Finch, Gilead, Janssen, Lycera, Merck, Otsuka, Pfizer, PureTech, and Seres and has received research support from Allakos, Artizan, NovoNordisk, and Pfizer. Edward L. Barnes has served as a consultant for AbbVie, Boomerang, Eli Lilly, Pfizer, Sanofi, Takeda, and Target RWE and has received research support from Eli Lilly. Meera Iyengar and Animesh Jain have no relevant disclosures for this work.
